The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:michael olise500+bank of america fine1000+club brugge200+rb leipzig200+anthony gordon500+mid atlantic ridge earthquakes500+montez sweat2000+rob lowe1000+

Category:All Headlines World & Geopolitics Markets & Economy Tech & AI PoliticsSearch results for: "Nilotinib versus imatinib" (30 stories)

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

Lead StoryNaturetech

Nov 18, 2025

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9jdVczODVTWHpueHloSnIwdWFNMXMxb2dCX2R4VXNVa0kzQWNZU0wtVS1JSVNtUzNCZGxLZGwzSkpEWkY5UExaaUxSQ0tJZFVvNGhNM2JpOFpJNkEzSmdF?oc=5" target="_blank">Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint</a>&nbsp;&nbsp;Nature

Read Full Story Related Trends

Google Trends & Trending Search Intelligence

Real-time search volume

500+15m ago

michael olise

Transfer Rumors: Liverpool Handed Olise Boost; Man Utd Battle Real Madrid for McTominay

Filter stories

1000+15m ago

bank of america fine

Bank of America fined $1.2 billion over money-laundering violations

Filter stories

200+15m ago

club brugge

LIVE: Dan toch 1-1! Club laat zich na penalty Tresoldi te makkelijk vangen, Lautaro zorgt voor gelijkmaker

Filter stories

200+15m ago

rb leipzig

Nach 6:0 in der Liga: Demichelis erwartet anderes Kaliber

Filter stories

Search Results for "Nilotinib versus imatinib"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial

The Lancetgeneral

May 1

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNXzBRdl9lVlRtYnNsRk5iSGtGZF82cmtJQVdfTWFTb1lHMUhVejM0eW9OcEszTjNwZTZsS3VmWlFQTVlEWGZOSHpCV19ULUh5OTJndTQ3QW5wTUplNnNZU2U2S0xfek9UVTMzLUxCb2hTbEE2RDJUbVRmTmRVLUQ4Yl9tc2xtV2otd28w?oc=5" target="_blank">Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial</a>&nbsp;&nbsp;The Lancet

World News, Markets & Google Trends

Top Headline Story

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

Google Trends & Trending Search Intelligence

michael olise

bank of america fine

club brugge

rb leipzig

Search Results for "Nilotinib versus imatinib"

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial

Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing

Effectiveness and Safety of Imatinib and Nilotinib in Chronic Myeloid Leukemia: A Single-Center Study From Southern Morocco

The Evolution of Tyrosine Kinase Inhibitor Therapy: Improving Outcomes in Patients with Newly Diagnosed Chronic Myelogenous Leukemia

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib

FDA OKs Oral Nilotinib Tablets in Ph+ Chronic Myeloid Leukemia

QOL, Efficacy, and Cost Considerations Help Drive TKI Treatment Selection in CML

Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

FDA Approves Cavhanza for PH-positive Chronic Myeloid Leukemia

Chronic Myeloid Leukemia Highlights From ASH 2025

FDA OKs Oral Nilotinib Tablets for Ph+ CML With Acid-Reducer Flexibility

Bone Marrow Aplasia Under Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Rare and Unpredictable Complication

FDA Approves Oral Nilotinib Tablets for Ph+ CML

Imatinib and nilotinib are equally successful in achieving therapy-free remission

Dr Jabbour on the Significance of the FDA Approval of Orally Disintegrating Nilotinib Tablets for CML

Nilotinib-Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case

Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

CML after imatinib: ponatinib linked to higher all-cause mortality vs nilotinib

Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results

Imatinib- and Nilotinib-Induced Lichenoid... : Indian Dermatology Online Journal

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?

Nilotinib as a risk factor for ischaemic stroke: a series of three cases

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data - Belohlavkova - 2024 - Cancer Medicine

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia